Metro G, Cappuzzo F (2009) Emerging drugs for small-cell lung cancer. Expert Opin Emerg Drugs14: 591-606.Metro G, Cappuzzo F (2009) Emerging drugs for small-cell lung cancer. Expert Opin Emerg Drugs 14: 591-606.Metro G, Cappuzzo F. Emerging drugs for small - cell lung cancer [ ...
Lung CancerEttinger DS. New drugs for treating small cell lung cancer. Lung Cancer 1995 Jun; 12 Suppl. 3: S53–61Ettinger, D. S. (1995). New drugs for treating small cell lung can- cer. Lung Cancer 12(Suppl. 3), S53-S61.
This cross-sectional study examines trends in costs of brand-name medications for treatment of non–small cell lung cancer and within-class price
So, 13% of non–small cell lung cancer will harbor KRAS G12C mutations. Now we have figured out how to target those with a drug that stops the cancer from growing, and this is a mutation that has been elusive in drug development for 30 years. It's important, ...
Docetaxel(also called Taxotere) is a yellow/brown concentrate which becomes colourless when diluted to the right concentration for use. It is used to treat non-small cell lung cancer (and also breast and prostate cancers). You may experience the more general side effects listed above. But Taxo...
以实习医院吉西他滨联合顺铂治疗非小细胞型肺癌患者的病例为研究对象,进行分析 Therefore the choice has in the multitudinous anti-tumor medicine in view of the non-cellule lung cancer medicine is the nowadays bigges[translate]
The results show that the 3D lung chip is better than the 2D well plate for the evaluation of the effects of the drugs on the non-small cell lung cancer NCI-H650 cell line, and the data from the microchip have more advantages, as they can more closely match the existing clinical drug...
FDA Approves Ensacove (ensartinib) for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma... 7 days ago New Drug Appr...
Opdivo (nivolumab), now available in a newly developed subcutaneous formulation, continues to show impressive results in non-small cell lung cancer (NSCLC) and other solid tumors. The subcutaneous version, tested in the CheckMate-67T trial, allows for faster administration, at three to five minute...
Scalpels, Beams, Drugs, and Dreams: Challenges of Stage IIIA-N2 Non–Small-Cell Lung Cancer The article discusses the challenges of stage IIIA non-small-cell lung cancer. It reveals that approximately 30 percent of patients who are newly diagnosed with non-small-cell lung cancers have locally...